Gapping up
M&A news: MRO +3.2% (acquires PayRock Energy Holdings for $888 mln), PRGO +1.4% (to sell its US vitamins, minerals, & supplements biz to International Vitamin)
M&A news: MRO +3.2% (acquires PayRock Energy Holdings for $888 mln), PRGO +1.4% (to sell its US vitamins, minerals, & supplements biz to International Vitamin)
Select EU financial related names showing strength following Brexit polls suggesting UK to remain in EU:RBS +8.6%, LYG +8.1%, BCS +7.8%, PUK +5.7%, DB +5%, HSBC +3.9%, ING +3.7%
Select large EU names trading higher: IHG +7%, SHPG +5.1%, AZN +4.8%, VOD +4.7%, GSK +4.7%, SNY+3.6%, MT +3.9%
Select oil/gas related names showing strength: CHK +8%, BAS +5.7%, YNDX +5.5%, SDRL +5%, WLL+4.4%, BP +4%
Other news: NVCN +35.5% (announces 'positive' results from a study using the Reducer product were published in The Netherlands Heart Journal documenting 23 consecutive patients implanted with Reducer to treat refractory angina), FATE +25% (receives FDA Fast Track Designation for ProTmune), CERS +11.8% (to receive up to $180 mln of funding over 5 years to advance its INTERCEPT red blood cell program), INO +5.5% (enters into At-the-Market Equity Offering Sales Agreement to sell up to $50 mln shares of common stock from time-to-time), ALLT +4% (continued strength), FCX +3.8% (copper futures up 1%+ this morning), JD +2.6% (rumored to be near a deal to acquire Walmart's (WMT) Yihaodian, according to Marbridge), HOLX +1.7% (FDA approves emergency authorization for Aptima Zika virus assay), AGN +1.5% (presents new data highlighting in vitro activity of Avycaz against several species of Gram-negative pathogens), GAIA +1.3% (announces extension to of the expiration date of its previously announced tender offer to purchase shares of its Common Stock), CXRX +1.2% (announces 'positive' findings from analysis of Photodynamic Therapy with Photofrin clinical data; settles arbitration with former financial advisor),CLRB +1.1% (files for 300,006 common share offering by selling shareholders; proposed max offering price $3.785/share), MNK +1.0% (granted orphan designation by the FDA for hydromorphone hydrochloride for the treatment of complex regional pain syndrome)
Analyst comments: YELP +5.9% (upgraded to Buy from Hold at Deutsche Bank), EXPE +5.4% (upgraded to Overweight from Neutral at Atlantic Equities), CTLT +2.8% (upgraded to Buy from Neutral at BofA/Merrill), SYMC+2.7% (upgraded to Buy from Sell at UBS), CMTL +2.2% (initiated with an Outperform at BMO Capital), UA +1.6% (upgraded to Buy from Neutral at Buckingham Research), GLW +1.4% (initiated with a Buy at Citigroup)